Ep. 106: On the Verge: Leaders in Bioscience Discuss the State of Vaccines and Treatments

podcast

Podcast Series

Ep. 106: On the Verge: Leaders in Bioscience Discuss the State of Vaccines and Treatments

Author(s)
Michael Milken
Michael Milken
Chairman, Milken Institute

Episode 106 : On the Verge: Leaders in Bioscience Discuss the State of Vaccines and Treatments

David Feinberg (Vice President, Google Health; Advisory Board Member, FasterCures), Esther Krofah (Executive Director, FasterCures)

“We're going to need vaccines to create as widespread herd immunity as we can, but we're also going to need drugs that are targeted against the virus that can provide immediate protection and also treat those who are already sick," says Regeneron Co-founder and Chief Scientific Officer, George Yancopoulos. "So we have multiple clinical trials ongoing with our antibody cocktail, both for prophylaxis or prevention and also for treatment.”

Three world-renowned bioscience leaders join Mike Milken and Prostate CancerFoundation (PCF) chief science officer Howard Soule for a conversation on the state of the COVID-19 challenge, herd immunity, and unique approaches to developing safe and effective vaccines, antibodies, and other treatments. Recorded on August 29 as part of a PCF event, this conversation is especially notable as it describes the antibody cocktail that would later be administered to President Donald Trump after he contracted the virus.

Moderna’s Tal Zaks is optimistic that scientists are on the verge of a breakthrough we’ll learn more about very soon. “In the coming months,” he tells Howard on the podcast, “expect data from us and potentially some of the other vaccine companies that also have started phase 3 trials that will conclusively demonstrate that these vaccines can work. I hope all of them succeed because I don't think a single company can carry the weight of what's needed to protect all of us and all those who need it.”

Published November 10, 2020